In conclusion, the evaluation of three miRNAs with recognized diagnostic potential for the differentiation of thyroid nodules, in combination with BRAF mutation and EU-TIRADS category assessment, supports clinical decision making in patients with thyroid nodules of category III. The gene discussed is BRAF; the disease is thyroid nodule.